Clearmind Medicine Inc.CMNDNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 3Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -41.05% |
| Q3 2025 | 59.92% |
| Q2 2025 | -8.20% |
| Q1 2025 | 0.39% |
| Q4 2024 | 41.36% |
| Q3 2024 | 8.84% |
| Q2 2024 | 44.89% |
| Q1 2024 | -41.42% |
| Q4 2023 | 47.92% |
| Q3 2023 | -19.43% |
| Q2 2023 | -44.67% |
| Q1 2023 | -55.40% |
| Q4 2022 | 296.12% |
| Q3 2022 | -72.42% |
| Q2 2022 | 277.07% |
| Q1 2022 | -26.54% |
| Q4 2021 | 895.39% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |